Press release
Ewing Sarcoma Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Nanovalent Pharma, Oncomatryx, Valent Technologies, Cellectar Biosciences, Eisai Inc
"Ewing Sarcoma Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/ewing-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Ewing Sarcoma Market.
The Ewing Sarcoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Ewing Sarcoma Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Ewing Sarcoma treatment therapies with a considerable amount of success over the years. Ewing Sarcoma Key players such as - Nanovalent Pharmaceuticals, Oncomatryx, Valent Technologies, Cellectar Biosciences, Eisai Inc., Shanghai Pharmaceuticals Holding, Exelixis, Gradalis, Inc., and others, are developing therapies for the Ewing Sarcoma treatment
*
Ewing Sarcoma Emerging therapies such as - NV-101, OMTX-703, VAL-413, CLR 131, Eribulin mesylate, TK216, Cabozantinib, Vigil EWS, and others are expected to have a significant impact on the Ewing Sarcoma market in the coming years.
*
In July 2025, Actuate Therapeutics, Inc. (NASDAQ: ACTU), a clinical-stage biopharmaceutical company developing treatments for challenging, high-impact cancers through GSK-3 inhibition, has announced the completion of the Phase 1 segment of its clinical trial (Actuate-1902). The study evaluated elraglusib as a monotherapy or in combination with irinotecan, irinotecan plus temozolomide, or cyclophosphamide plus topotecan in pediatric patients with relapsed cancers. Encouraging signs of efficacy were observed, especially in treatment-resistant Ewing Sarcoma (EWS), a rare soft tissue and bone tumor. Based on these results, the company plans to move forward with a Phase 2 trial involving children, adolescents, and adults with relapsed/refractory EWS.
*
In November 2024, The FDA awarded rare pediatric disease designation to elraglusib (9-ING-41), an innovative GSK-3 inhibitor, as a potential treatment for Ewing sarcoma. The investigational therapy is currently being assessed in the open-label, multicenter Phase 1/2 Actuate-1902 trial (NCT04239092), which is examining its safety and efficacy in pediatric patients with relapsed or refractory cancers, including Ewing sarcoma and related small round cell sarcomas.
Ewing Sarcoma Overview
Ewing sarcoma is a rare type of cancer that primarily affects the bones or soft tissues. It most commonly occurs in children and young adults, typically between the ages of 10 and 20, but it can also occur in older adults. Ewing sarcoma most often arises in the bones of the pelvis, thighs, upper arms, or chest wall.
Get a Free Sample PDF Report to know more about Ewing Sarcoma Pipeline Assessment-
https://www.delveinsight.com/report-store/ewing-sarcoma-pipeline-insight [https://www.delveinsight.com/report-store/ewing-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Ewing Sarcoma Pipeline Therapeutics Assessment
*
Ewing Sarcoma Assessment by Product Type
*
Ewing Sarcoma By Stage and Product Type
*
Ewing Sarcoma Assessment by Route of Administration
*
Ewing Sarcoma By Stage and Route of Administration
*
Ewing Sarcoma Assessment by Molecule Type
*
Ewing Sarcoma by Stage and Molecule Type
DelveInsight's Ewing Sarcoma Report covers around 25+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Emerging Ewing Sarcoma Drugs Under Different Phases of Clinical Development Include:
*
NV-101: Nanovalent Pharmaceuticals
*
OMTX-703: Oncomatryx
*
VAL-413: Valent Technologies
*
CLR 131: Cellectar Biosciences
*
Eribulin mesylate: Eisai Inc.
*
TK216: Shanghai Pharmaceuticals Holding
*
Cabozantinib: Exelixis
*
Vigil EWS: Gradalis, Inc.
Download Sample PDF Report to know more about Ewing Sarcoma drugs and therapies [https://www.delveinsight.com/sample-request/ewing-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Ewing Sarcoma Pipeline Analysis:
The Ewing Sarcoma pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the Ewing Sarcoma treatment with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ewing Sarcoma Treatment.
*
Ewing Sarcoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Ewing Sarcoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ewing Sarcoma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Ewing Sarcoma product details are provided in the report. Download the Ewing Sarcoma pipeline report to learn more about the emerging Ewing Sarcoma therapies [https://www.delveinsight.com/sample-request/ewing-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Ewing Sarcoma Pipeline Market Drivers
*
Rising awareness about Ewing Sarcoma and financial assistance programs
*
Demand for New and Effective Drugs
Ewing Sarcoma Pipeline Market Barriers
*
Lack of approved therapies for Ewing's sarcoma
*
Absence of predictive biomarkers in Ewing's sarcoma
Scope of Ewing Sarcoma Pipeline Drug Insight
*
Coverage: Global
*
Key Ewing Sarcoma Companies: Nanovalent Pharmaceuticals, Oncomatryx, Valent Technologies, Cellectar Biosciences, Eisai Inc., Shanghai Pharmaceuticals Holding, Exelixis, Gradalis, Inc., and others
*
Key Ewing Sarcoma Therapies: NV-101, OMTX-703, VAL-413, CLR 131, Eribulin mesylate, TK216, Cabozantinib, Vigil EWS, and others
*
Ewing Sarcoma Therapeutic Assessment: Ewing Sarcoma current marketed and Ewing Sarcoma emerging therapies
*
Ewing Sarcoma Market Dynamics: Ewing Sarcoma market drivers and Ewing Sarcoma market barriers
Request for Sample PDF Report for Ewing Sarcoma Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/ewing-sarcoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1
Ewing Sarcoma Report Introduction
2
Ewing Sarcoma Executive Summary
3
Ewing Sarcoma Overview
4
Ewing Sarcoma- Analytical Perspective In-depth Commercial Assessment
5
Ewing Sarcoma Pipeline Therapeutics
6
Ewing Sarcoma Late Stage Products (Phase II/III)
7
Ewing Sarcoma Mid Stage Products (Phase II)
8
Ewing Sarcoma Early Stage Products (Phase I)
9
Ewing Sarcoma Preclinical Stage Products
10
Ewing Sarcoma Therapeutics Assessment
11
Ewing Sarcoma Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
Ewing Sarcoma Key Companies
14
Ewing Sarcoma Key Products
15
Ewing Sarcoma Unmet Needs
16
Ewing Sarcoma Market Drivers and Barriers
17
Ewing Sarcoma Future Perspectives and Conclusion
18
Ewing Sarcoma Analyst Views
19
Appendix
20
About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=ewing-sarcoma-pipeline-2025-key-companies-moa-roa-and-clinical-trials-evaluation-by-delveinsight-nanovalent-pharma-oncomatryx-valent-technologies-cellectar-biosciences-eisai-inc]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Ewing Sarcoma Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Nanovalent Pharma, Oncomatryx, Valent Technologies, Cellectar Biosciences, Eisai Inc here
News-ID: 4133947 • Views: …
More Releases from ABNewswire
Top 6 Deck Builders In Kansas City For Stunning Outdoor Spaces
Outdoor living has evolved to become something more.
It is now a lifestyle choice.
Today's families seek spaces that harmonize with the natural world, yet remain as comfortable and well-designed as rooms in their homes. Patios and pergolas aren't an afterthought, but an absolute must that adds significant value to your property and makes everyday life better.
In areas with seasonal weather, where people can be outside for most of the year, homeowners…
Dash Capital Expands Zero Interest Business Loans in Detroit Following Unprecede …
Dash Capital's expansion in Detroit reflects strong demand from local businesses for flexible, fast funding solutions that support growth and operational needs across the Motor City's diverse economic landscape.
The Detroit business landscape continues to show remarkable resilience and growth potential, prompting Dash Capital to expand its funding programs in response to overwhelming demand from local entrepreneurs. This expansion comes at a time when Motor City businesses are actively seeking alternative…
Jacksonville Family Business Expands Concrete Washing Services Amid Growing Prop …
Nubirth Pressure Washing, a family-owned company serving Jacksonville since 2004, reflects the growing demand for specialized exterior property cleaning in Northeast Florida, offering comprehensive surface restoration services.
Jacksonville, FL - The Northeast Florida property maintenance industry has witnessed significant growth in specialized cleaning services as homeowners and businesses prioritize exterior property care. Local family-owned company Nubirth Pressure Washing [https://www.google.com/maps/place/Nubirth+Pressure+Washing/@30.3340387,-81.7122184,17z/data=!3m1!4b1!4m6!3m5!1s0x88e5b9c01d715555:0xd2c2470a4640f2be!8m2!3d30.3340387!4d-81.7122184!16s%2Fg%2F11vk2l_v57!5m1!1e3?entry=ttu&g_ep=EgoyMDI1MDgyNS4wIKXMDSoASAFQAw%3D%3D] represents this trend, having served the Jacksonville area since 2004 with comprehensive…
A-Class Moving & Storage Expands Direct Delivery Network, Positioning Miramar Mo …
A-Class Moving & Storage, based in Miramar, has expanded its direct delivery network across South Florida, strengthening its position as a leading moving company and reliable alternative to traditional van line brokers. The growth allows the family-owned business to serve more customers while preserving its personalized service standards.
A-Class Moving & Storage has announced a significant expansion of its direct delivery network throughout South Florida, establishing the business as a leading…
More Releases for Ewing
Pioneering Advances Propel the Ewing Sarcoma Drugs Market to New Heights
The global Ewing sarcoma drugs market is poised for remarkable growth over the next decade, driven by scientific breakthroughs, robust pipeline portfolios, and an increasing focus on targeted therapies. Once a niche segment within oncology, treatments for Ewing sarcoma-an aggressive bone and soft-tissue tumor predominantly affecting children, adolescents, and young adults-are rapidly evolving from broad-spectrum chemotherapeutic regimens to precision medicines that promise improved outcomes and reduced toxicity.
The global Ewing sarcoma…
Mad Max Publishing Announces Newest Best-Selling Author Hunter Ewing
Image: https://www.abnewswire.com/upload/2025/04/6dbb7a2237180d135128f8603075b1f4.jpg
Doral, FL - Mad Max Publishing, announced its newest bestselling author Hunter Ewing, who's recently released book, "The Playmaker" quickly climbed the charts to become a number one bestseller.
Published, Promoted and Reached #1 National Bestseller on Amazon.
Hunter Ewing is the #1 Best-Selling Author of The Playmaker , a powerful guide that equips business owners with branding strategies to rise above their competition and dominate their niche. A former college…
Ewing Sarcoma Pipeline, FDA Approvals, Clinical Trials, and Companies 2024 (Upda …
DelveInsight's, "Ewing Sarcoma Pipeline Insights 2024" report provides comprehensive insights about 25+ Ewing Sarcoma companies and 25+ pipeline drugs in the Ewing Sarcoma pipeline landscape. It covers the Ewing Sarcoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Ewing Sarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways…
Ewing Sarcoma Pipeline, FDA Approvals, Clinical Trials Developments, and Compani …
DelveInsight's, "Ewing Sarcoma Pipeline Insights" report provides comprehensive insights about 25+ Ewing Sarcoma companies and 25+ pipeline drugs in the Ewing Sarcoma pipeline landscape. It covers the Ewing Sarcoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Ewing Sarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from…
Ewing Sarcoma Drugs Market is Booming Worldwide with CAGR of 5.6%
The global and Middle East Africa Ewing Sarcoma Drugs Market is the most recent research report from USD Analytics that analyses market risk side data, highlights opportunities, and uses that data to support tactical as well as strategic decision-making. A thorough investigation was conducted to provide the most recent information on the market's key characteristics for Ewing Sarcoma Drugs. Regarding revenue size, production, CAGR, consumption, gross margin, pricing, and other…
Global Ewing Sarcoma Drugs Market Size, Share, Growth & Forecast 2023-2032
In the forecasted period from 2022 to 2030, the market for medications to treat ewing sarcoma is anticipated to expand at a CAGR of 5.5%. The rise in ewing sarcoma cases, more knowledge of the disease and its treatments, and the introduction of innovative therapeutics for the illness are all factors contributing to the market's expansion. Based on type, application, and location, the market for ewing sarcoma medications is divided…
